Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
The mechanisms of action of proteasome inhibitors (PI) in multiple myeloma (MM) treatment are not fully elucidated. Here, the authors use unbiased phosphoproteomics in PI-treated MM and show increased phosphorylation of splicing-associated proteins, ultimately revealing splicing interference as a mo...
Guardado en:
Autores principales: | Hector H. Huang, Ian D. Ferguson, Alexis M. Thornton, Prabhakar Bastola, Christine Lam, Yu-Hsiu T. Lin, Priya Choudhry, Margarette C. Mariano, Makeba D. Marcoulis, Chin Fen Teo, Julia Malato, Paul J. Phojanakong, Thomas G. Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Byron Hann, Angela N. Brooks, Arun P. Wiita |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ede6677994c4ad081bb8e902cda0b7a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
por: Feng Ge, et al.
Publicado: (2010) -
Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Ajai Chari, et al.
Publicado: (2010) -
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Melissa K. Bennett, et al.
Publicado: (2022) -
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Shansa Pranami E. Jayaweera, et al.
Publicado: (2021) -
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
por: Yurie Nagai, et al.
Publicado: (2021)